photosensitizer

(redirected from Photosensitiser)
Also found in: Dictionary, Medical.

photosensitizer

[¦fōd·ō′sen·sə‚tīz·ər]
(physical chemistry)
A light-absorbing substance that initiates a photochemical or photophysical reaction in another substance (molecule), and is not consumed in the reaction.
References in periodicals archive ?
The subject of the tender is the delivery time resolved spectrofluorimeter, allowing the detection of luminescence with high temporal and spectral resolution, with emphasis on the possibility of direct detection of singlet oxygen (1270 nm) and singlet oxygen sensitized delayed fluorescence porfyrinoidnE[degrees]ch photosensitiser (600-700 nm).
In this review, recent developments in photosensitiser families are discussed with respect to in vitro performance indicators and to potential application in oncology.
The research team -- from the University of Hull's Department of Chemistry -- placed one kind of photosensitiser inside each nanoparticle and another on the outside, which meant that far more reactive oxygen species could be created from the same amount of light.
The cells were incubated in dark in 96-well plates with different concentrations of the Sn(IV) chlorin e6 photosensitiser (10, 15, 20, 25 and 30 [micro]g/ml) and was not treated with light.
PCI's proprietary photosensitiser Amphinex(R) is in this study combined with the therapeutic agent bleomycin.
The last patient has been treated with the company's proprietary photosensitiser Amphinex[R] used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London.
Pharmacy researchers at Queen's University in Belfast are working on a way to deliver the photosensitiser drug directly to the colon, avoiding side effects.
The biolitec Group, headquartered in Jena, Germany, is a biopharmaceutical company involved in the development and production of photosensitiser drugs for use in Photodynamic Therapy (PDT) and is a leading developer and manufacturer of diode lasers, optical fibers and accessories for application in a wide range of medical specialties.
OSLO -- PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex[R] used in combination with the cytotoxic agent bleomycin in cancer patients.